- BGI Genomics Announces Pricing of Initial Public Offering
- BGI Launches the Latest Desktop Sequencer BGISEQ-50
- International Science Community Welcomes China National GeneBank Opening
- BGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision Medicine
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- The Evolution of Chronic Lymphocytic Leukemia Revealed
- BGI involved in publication of the first seahorse genome in Nature
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
- Mapping more genomes will create a healthcare 'big data revolution'
Tel: +86-755-36307212Email: email@example.com
SHENZHEN, China (October 31, 2017) -- MGI Tech, a subsidiary corporation of BGI, launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200, at the 12th International Conference on Genomics (ICG-12) in Shenzhen. The products were unveiled at the conference, held at the China National GeneBank from Oct. 26 - 29 with the theme “Omics for All – Global Partnership.” MGI also launched a modular NGS workstation, MGIFLP, as well as a robotic ultrasound system, MGIUS-R3.
Before the product launch, BGI President Jian Wang gave the opening address. He said he hoped the new products could be affordable and benefit people all over the world, summing up his intention to “lower the price, save the life.”
MGI Vice-President Hui Jiang said the new sequencers will deliver consistent high quality sequencing data faster and at a lower price. MGISEQ 200/2000 are upgrades to BGISEQ 50/500 with technological improvements.
“MGISEQ-2000 and MGISEQ-200 can complete one run with PE100 read length in less than 48 hours, which provides partners high-quality service and data even more rapidly to benefit patients,” Jiang said.
“We have made significant improvements in the industrial design of the sequencers and optimized the chemistry, which will allow our customers to operate the sequencers in their labs at a lower cost,” said Jian Liu, MGI Vice President. MGISEQ-2000 and MGISEQ-200 can run with at least four different read lengths, providing flexibility to cover a wide variety of applications across genomic research, clinical diagnosis, agriculture, forensics and environmental engineering. “With our R&D team’s great efforts, we managed to make sequencing more affordable and of better quality and performance,” he said.
Several partners involved in early testing of the new technology said it demonstrates significant improvements over existing technology.
“MGISEQ-2000 is a great choice for genome sequencing. We can see both the consistency and data quality are satisfied, as well as an obvious improvement compared to BGISEQ-500, ”said Dr. David Smith, director of the Mayo Clinic’s Technology Assessment Group at the Center for Individualized Medicine, one of the early evaluators of MGISEQ-2000.
MGI Tech’s overall goal is to make the MGISEQ a versatile and open sequencing platform, said MGI CEO Feng Mu. MGI plans to release sequencing adapters and the test data to encourage users to develop their own applications on the MGISEQ platform.
“This will help us to speed up technology development and production and to provide better tools and services to our customers,” Mu said. “Our goal is to innovate new technologies to help people live a healthy life. That’s why ‘Omics for All” is the important theme of this year’s ICG.”
MGISEQ-2000 and MGISEQ-200 will be available for orders beginning from Dec. 25, 2017, and will start shipment from Feb. 14, 2018, initially in China.
MGI (MGI Tech Co., Limited) is a part of BGI Group, one of the world's largest genomics organizations. As the equipment supporting platform of BGI, MGI is dedicated to developing, manufacturing and distributing instruments, reagents and devices/assays through innovation and collaboration. Since its acquisition of CGI (Complete Genomics Inc.)), MGI has built upon its technologies to rapidly develop a new series of genetic sequencers, including BGISEQ-1000, BGISEQ-500, and BGISEQ-50. MGI's mission is to "Make a Great Instrument and Make It Smart" to provide a real-time, digitized panoramic view of living things and advance life science to service genomics, proteomics and beyond.